Increased	0	9	O
serum	10	15	B-Organism_substance
levels	16	22	O
of	23	25	O
vascular	26	34	B-Gene_or_gene_product
endothelial	35	46	I-Gene_or_gene_product
growth	47	53	I-Gene_or_gene_product
factor	54	60	I-Gene_or_gene_product
in	61	63	O
patients	64	72	B-Organism
with	73	77	O
renal	78	83	B-Pathological_formation
cell	84	88	I-Pathological_formation
carcinoma	89	98	I-Pathological_formation
.	98	99	O

Neovascularization	101	119	O
,	119	120	O
an	121	123	O
essential	124	133	O
event	134	139	O
for	140	143	O
the	144	147	O
growth	148	154	O
of	155	157	O
solid	158	163	B-Pathological_formation
tumors	164	170	I-Pathological_formation
,	170	171	O
is	172	174	O
regulated	175	184	O
by	185	187	O
a	188	189	O
number	190	196	O
of	197	199	O
angiogenic	200	210	O
factors	211	218	O
.	218	219	O

One	220	223	O
such	224	228	O
factor	229	235	O
,	235	236	O
vascular	237	245	B-Gene_or_gene_product
endothelial	246	257	I-Gene_or_gene_product
growth	258	264	I-Gene_or_gene_product
factor	265	271	I-Gene_or_gene_product
(	272	273	O
VEGF	273	277	B-Gene_or_gene_product
)	277	278	O
,	278	279	O
is	280	282	O
considered	283	293	O
to	294	296	O
exert	297	302	O
a	303	304	O
potent	305	311	O
angiogenic	312	322	O
activity	323	331	O
,	331	332	O
as	333	335	O
indicated	336	345	O
by	346	348	O
immunohistochemical	349	368	O
and	369	372	O
molecular	373	382	O
evidence	383	391	O
.	391	392	O

In	393	395	O
this	396	400	O
study	401	406	O
we	407	409	O
investigated	410	422	O
the	423	426	O
serum	427	432	B-Organism_substance
VEGF	433	437	B-Gene_or_gene_product
level	438	443	O
(	444	445	O
s	445	446	O
-	446	447	O
VEGF	447	451	B-Gene_or_gene_product
)	451	452	O
in	453	455	O
patients	456	464	B-Organism
with	465	469	O
renal	470	475	B-Pathological_formation
cell	476	480	I-Pathological_formation
carcinoma	481	490	I-Pathological_formation
(	491	492	O
RCC	492	495	B-Pathological_formation
)	495	496	O
.	496	497	O

s	498	499	O
-	499	500	O
VEGF	500	504	B-Gene_or_gene_product
in	505	507	O
peripheral	508	518	B-Organism_substance
blood	519	524	I-Organism_substance
samples	525	532	I-Organism_substance
was	533	536	O
analyzed	537	545	O
in	546	548	O
40	549	551	O
RCC	552	555	B-Pathological_formation
patients	556	564	B-Organism
and	565	568	O
40	569	571	O
patients	572	580	B-Organism
without	581	588	O
cancer	589	595	B-Pathological_formation
(	596	597	O
controls	597	605	O
)	605	606	O
using	607	612	O
a	613	614	O
sandwich	615	623	O
enzyme	624	630	O
-	630	631	O
linked	631	637	O
immunoassay	638	649	O
.	649	650	O

In	651	653	O
20	654	656	O
RCC	657	660	B-Pathological_formation
patients	661	669	B-Organism
,	669	670	O
serum	671	676	B-Organism_substance
samples	677	684	I-Organism_substance
were	685	689	O
obtained	690	698	O
separately	699	709	O
from	710	714	O
the	715	718	O
bilateral	719	728	B-Multi-tissue_structure
renal	729	734	I-Multi-tissue_structure
veins	735	740	I-Multi-tissue_structure
.	740	741	O

s	742	743	O
-	743	744	O
VEGF	744	748	B-Gene_or_gene_product
was	749	752	O
also	753	757	O
measured	758	766	O
before	767	773	O
,	773	774	O
4	775	776	O
and	777	780	O
8	781	782	O
weeks	783	788	O
after	789	794	O
nephrectomy	795	806	O
in	807	809	O
11	810	812	O
patients	813	821	B-Organism
.	821	822	O

There	823	828	O
were	829	833	O
significant	834	845	O
differences	846	857	O
in	858	860	O
s	861	862	O
-	862	863	O
VEGF	863	867	B-Gene_or_gene_product
between	868	875	O
the	876	879	O
RCC	880	883	B-Pathological_formation
patients	884	892	B-Organism
and	893	896	O
the	897	900	O
controls	901	909	O
(	910	911	O
207	911	914	O
.	914	915	O
3	915	916	O
+	916	917	O
/	917	918	O
-	918	919	O
32	919	921	O
.	921	922	O
9	922	923	O
vs	924	926	O
.	926	927	O
71	928	930	O
.	930	931	O
5	931	932	O
+	932	933	O
/	933	934	O
-	934	935	O
9	935	936	O
.	936	937	O
1	937	938	O
pg	939	941	O
/	941	942	O
ml	942	944	O
,	944	945	O
mean	946	950	O
+	950	951	O
/	951	952	O
-	952	953	O
SE	953	955	O
)	955	956	O
(	957	958	O
P	958	959	O
less	960	964	O
than	965	969	O
0	970	971	O
.	971	972	O
005	972	975	O
)	975	976	O
,	976	977	O
between	978	985	O
the	986	989	O
tumor	990	995	B-Pathological_formation
-	995	996	O
bearing	996	1003	O
renal	1004	1009	B-Multi-tissue_structure
veins	1010	1015	I-Multi-tissue_structure
and	1016	1019	O
the	1020	1023	O
contralateral	1024	1037	O
ones	1038	1042	O
(	1043	1044	O
P	1044	1045	O
less	1046	1050	O
than	1051	1055	O
0	1056	1057	O
.	1057	1058	O
01	1058	1060	O
)	1060	1061	O
,	1061	1062	O
between	1063	1070	O
the	1071	1074	O
pre	1075	1078	O
-	1078	1079	O
and	1080	1083	O
post	1084	1088	O
-	1088	1089	O
nephrectomy	1089	1100	O
situations	1101	1111	O
(	1112	1113	O
P	1113	1114	O
less	1115	1119	O
than	1120	1124	O
0	1125	1126	O
.	1126	1127	O
01	1127	1129	O
)	1129	1130	O
and	1131	1134	O
among	1135	1140	O
the	1141	1144	O
various	1145	1152	O
parameters	1153	1163	O
of	1164	1166	O
tumor	1167	1172	B-Pathological_formation
status	1173	1179	O
such	1180	1184	O
as	1185	1187	O
tumor	1188	1193	B-Pathological_formation
extent	1194	1200	O
(	1201	1202	O
P	1202	1203	O
less	1204	1208	O
than	1209	1213	O
0	1214	1215	O
.	1215	1216	O
001	1216	1219	O
)	1219	1220	O
and	1221	1224	O
existence	1225	1234	O
of	1235	1237	O
metastasis	1238	1248	B-Pathological_formation
(	1249	1250	O
P	1250	1251	O
less	1252	1256	O
than	1257	1261	O
0	1262	1263	O
.	1263	1264	O
001	1264	1267	O
)	1267	1268	O
.	1268	1269	O

s	1270	1271	O
-	1271	1272	O
VEGF	1272	1276	B-Gene_or_gene_product
significantly	1277	1290	O
correlated	1291	1301	O
with	1302	1306	O
the	1307	1310	O
tumor	1311	1316	B-Pathological_formation
volume	1317	1323	O
obtained	1324	1332	O
by	1333	1335	O
a	1336	1337	O
three	1338	1343	O
-	1343	1344	O
dimensional	1344	1355	O
measurement	1356	1367	O
(	1368	1369	O
r	1369	1370	O
=	1370	1371	O
0	1371	1372	O
.	1372	1373	O
802	1373	1376	O
,	1376	1377	O
P	1378	1379	O
less	1380	1384	O
than	1385	1389	O
0	1390	1391	O
.	1391	1392	O
0001	1392	1396	O
)	1396	1397	O
.	1397	1398	O

The	1399	1402	O
sensitivity	1403	1414	O
and	1415	1418	O
specificity	1419	1430	O
of	1431	1433	O
s	1434	1435	O
-	1435	1436	O
VEGF	1436	1440	B-Gene_or_gene_product
at	1441	1443	O
the	1444	1447	O
cut	1448	1451	O
-	1451	1452	O
off	1452	1455	O
level	1456	1461	O
of	1462	1464	O
100	1465	1468	O
pg	1469	1471	O
/	1471	1472	O
ml	1472	1474	O
,	1474	1475	O
as	1476	1478	O
determined	1479	1489	O
by	1490	1492	O
the	1493	1496	O
receiver	1497	1505	O
-	1505	1506	O
operating	1506	1515	O
-	1515	1516	O
characteristics	1516	1531	O
curve	1532	1537	O
,	1537	1538	O
were	1539	1543	O
80	1544	1546	O
.	1546	1547	O
0	1547	1548	O
%	1548	1549	O
and	1550	1553	O
72	1554	1556	O
.	1556	1557	O
5	1557	1558	O
%	1558	1559	O
,	1559	1560	O
respectively	1561	1573	O
.	1573	1574	O

The	1575	1578	O
results	1579	1586	O
indicate	1587	1595	O
that	1596	1600	O
tumor	1601	1606	B-Tissue
tissue	1607	1613	I-Tissue
of	1614	1616	O
RCC	1617	1620	B-Pathological_formation
liberates	1621	1630	O
VEGF	1631	1635	B-Gene_or_gene_product
into	1636	1640	O
the	1641	1644	O
systemic	1645	1653	O
blood	1654	1659	B-Organism_substance
flow	1660	1664	O
and	1665	1668	O
that	1669	1673	O
s	1674	1675	O
-	1675	1676	O
VEGF	1676	1680	B-Gene_or_gene_product
is	1681	1683	O
a	1684	1685	O
possible	1686	1694	O
marker	1695	1701	O
for	1702	1705	O
RCC	1706	1709	B-Pathological_formation
.	1709	1710	O

